Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma

doi:10.3760/cma.j.cn371439-20200610-00022

Abstract

Abstract:

Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of the confirmed cases of esophageal cancer in Asia, and the degree of malignancy is high. There is a growing number of research on ESCC immunotherapy, particularly programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). Among them, the most studied PD-1/PD-L1 inhibitors in ESCC are nivolumab, pembrolizumab, camrelizumab, toripalimab, tislelizumab, atozolizumab, SHR-1316 and durvalumab. Some of the clinical trials of these drugs are still in progress, and some have initially shown good results.

Key words: Esophageal neoplasms, Neoplasms, squamous cell, PD-1, PD-L1

Ding Yan, Wang Hongyan. Advances of PD-1/PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2021, 48(2): 113-116.

References 24

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Zeng H, Zheng R, Zhang S, et al. Esophageal cancer statistics in China, 2011: estimates based on 177 cancer registries[J]. Thoracic Cancer, 2016,7(2):232-237. DOI: 10.1111/1759-7714.12322. doi: 10.1111/1759-7714.12322 pmid: 27042227
[3]	Sharma P, Allison JP. The future of immune checkpoint therapy[J]. Science, 2015,348(6230):56-61. DOI: 10.1126/science.aaa8172. pmid: 25838373
[4]	Mimura K, Yamada L, Ujiie D, et al. Immunotherapy for esophageal squamous cell carcinoma: a review[J]. Fukushima J Med Sci, 2018,64(2):46-53. DOI: 10.5387/fms.2018-09. pmid: 30058598
[5]	Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017,18(5):631-639. DOI: 10.1016/S1470-2045(17)30181-X. doi: 10.1016/S1470-2045(17)30181-X pmid: 28314688
[6]	Kato K, Doki Y, Ura T, et al. Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer[J]. Cancer Sci, 2020,111(5):1676-1684. DOI: 10.1111/cas.14380. pmid: 32160365
[7]	Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemothe-rapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019,20(11):1506-1517. DOI: 10.1016/S1470-2045(19)30626-6. doi: 10.1016/S1470-2045(19)30626-6 pmid: 31582355
[8]	Yamamoto S, Kato K, Daiko H, et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: frontier (JCOG1804E)[J]. Future Oncol, 2020,16(19):1351-1357. DOI: 10.2217/fon-2020-0189. doi: 10.2217/fon-2020-0189 pmid: 32396014
[9]	Meindl-Beinker NM, Betge J, Gutting T, et al. A multicenter open-label phaseⅡ trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)[J]. BMC Cancer, 2019,19(1):231. DOI: 10.1186/s12885-019-5446-2. doi: 10.1186/s12885-019-5446-2 pmid: 30871493
[10]	Doi T, Piha-Paul SA, Jalal SI, et al. Safety and antitumor activity of the anti-programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma[J]. J Clin Oncol, 2018,36(1):61-67. DOI: 10.1200/JCO.2017.74.9846. doi: 10.1200/JCO.2017.74.9846 pmid: 29116900
[11]	Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study[J]. JAMA Oncol, 2019,5(4):546-550. DOI: 10.1001/jamaoncol.2018.5441. doi: 10.1001/jamaoncol.2018.5441 pmid: 30570649
[12]	Kojima T, Muro K, Francois E, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase Ⅲ KEYNOTE-181 study[J]. J Clin Oncol, 2019,37(4_suppl):2. DOI: 10.1200/JCO.2019.37.4_suppl.2.
[13]	Barsouk A, Rawla P, Hadjinicolaou AV, et al. Targeted therapies and immunotherapies in the treatment of esophageal cancers[J]. Med Sci (Basel), 2019,7(10):100. DOI: 10.3390/medsci7100100.
[14]	Kato K, Shah MA, Enzinger P, et al. KEYNOTE-590: Phase Ⅲ study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer[J]. Future Oncol, 2019,15(10):1057-1066. DOI: 10.2217/fon-2018-0609. doi: 10.2217/fon-2018-0609 pmid: 30735435
[15]	Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2020,21(6):832-842. DOI: 10.1016/S1470-2045(20)30110-8. doi: 10.1016/S1470-2045(20)30110-8 pmid: 32416073
[16]	Mo H, Huang J, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study[J]. Br J Cancer, 2018,119(5):538-545. DOI: 10.1038/s41416-018-0100-3. doi: 10.1038/s41416-018-0100-3 pmid: 29755117
[17]	Huang J, Xu B, Mo H, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma[J]. Clin Cancer Res, 2018,24(6):1296-1304. DOI: 10.1158/1078-0432.CCR-17-2439. doi: 10.1158/1078-0432.CCR-17-2439 pmid: 29358502
[18]	Finlay WJJ, Coleman JE, Edwards JS, et al. Anti-PD1 'SHR-1210' aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement[J]. MAbs, 2019,11(1):26-44. DOI: 10.1080/19420862.2018.1550321. doi: 10.1080/19420862.2018.1550321 pmid: 30541416
[19]	Zhang B, Wang X, Li Q, et al. Efficacy of irinotecan-based chemotherapy after exposure to an anti-PD-1 antibody in patients with advanced esophageal squamous cell carcinoma[J]. Chin J Cancer Res, 2019,31(6):910-917. DOI: 10.21147/j.issn.1000-9604.2019.06.07. doi: 10.21147/j.issn.1000-9604.2019.06.07 pmid: 31949393
[20]	Wang X, Zhang B, Chen X, et al. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esopha-geal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody[J]. Thorac Cancer, 2019,10(6):1395-1401. DOI: 10.1111/1759-7714.13083. pmid: 31017739
[21]	Wang F, Wei XL, Wang FH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ⅰb/Ⅱ clinical trial NCT02915432[J]. Ann Oncol, 2019,30(9):1479-1486. DOI: 10.1093/annonc/mdz197. doi: 10.1093/annonc/mdz197 pmid: 31236579
[22]	Xu J, Bai Y, Xu N, et al. Tislelizumab plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma[J]. Clin Cancer Res, 2020,26(17):4542-4550. DOI: 10.1158/1078-0432.CCR-19-3561. doi: 10.1158/1078-0432.CCR-19-3561 pmid: 32561664
[23]	Bando H, Kotani D, Tsushima T, et al. TENERGY: multicenter phase Ⅱ study of Atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma[J]. BMC Cancer, 2020,20(1):336. DOI: 10.1186/s12885-020-06716-5. pmid: 32312286
[24]	Guimbaud R, Quéro L, Vendrely V, et al. Prodige67_ucgi33 arion: association of radiochemotherapy and immunotherapy for the treatment of unresectable oesophageal cancer: a comparative randomized phase Ⅱ trial[J]. Ann Oncol, 2019,30(suppl_5):v322. DOI: 10.1093/annonc/mdz247.163.